{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T10:09:16Z","timestamp":1788775756219,"version":"build-2803163510"},"reference-count":158,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T00:00:00Z","timestamp":1788652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Colorectal cancer (CRC) has shown significant heterogeneity regarding its response to immunotherapy. Long-lasting, beneficial effects have been observed in mismatch repair-deficient, microsatellite instability-high (dMMR\/MSI-H) tumours, while mismatch repair-proficient, microsatellite stable (pMMR\/MSS) tumours have remained resistant. Such differences in results have been studied in this review through the \u201chot\u201d and \u201ccold\u201d tumour concept. It explains how various biological and microenvironmental factors play a role in immune resistance and T-cell priming and infiltration. Key factors include a low neoantigen load and defects in antigen presentation, which reduce the overall immune recognition of tumour cells. The review also studies certain processes such as Wnt\/\u03b2-catenin and mitogen-activated protein kinase (MAPK) signalling and what input they have in the prevention of effective antitumour immune responses. Conventional treatments like chemotherapy and radiotherapy have been considered alongside more targeted treatments such as the inhibition of vascular endothelial growth factor (VEGF) signalling and the suppression of myeloid-mediated immune evasion, to convert \u201ccold\u201d MSS tumours into immune-responsive lesions. Methods which aim to modify the tumour microenvironment such as metabolic reprogramming and microbiome modulation have also been covered in this review. Artificial intelligence and nanomedicine are new technologies that could provide improved patient stratification and therapeutic precision, although their clinical application in pMMR\/MSS CRC remains under investigation. A systematic literature search of PubMed and PubMed Central (PMC) was conducted from 10 June 2026 to 19 August 2026 using predefined eligibility criteria, with study selection reported according to PRISMA 2020. Because of substantial heterogeneity in study design, therapeutic approach and reported outcomes, the included evidence was synthesized narratively rather than by meta-analysis. A total of 158 studies were included.<\/jats:p>","DOI":"10.3390\/molecules31173124","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T09:23:37Z","timestamp":1788773017000},"page":"3124","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Heating the Cold: Overcoming Immunotherapy Resistance in Microsatellite-Stable Colorectal Cancer: A Systematic Review"],"prefix":"10.3390","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5557-5464","authenticated-orcid":false,"given":"Dorota","family":"Bartusik-Aebisher","sequence":"first","affiliation":[{"name":"Department of Biochemistry and General Chemistry, Faculty of Medicine, Collegium Medicum, University of Rzeszow, 35-310 Rzeszow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4115-7779","authenticated-orcid":false,"given":"Daniel Roshan","family":"Justin Raj","sequence":"additional","affiliation":[{"name":"English Division Science Club, Faculty of Medicine, Collegium Medicum, University of Rzeszow, 35-310 Rzeszow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0829-7128","authenticated-orcid":false,"given":"Izabella","family":"Wilk","sequence":"additional","affiliation":[{"name":"English Division Science Club, Faculty of Medicine, Collegium Medicum, University of Rzeszow, 35-310 Rzeszow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2661-6570","authenticated-orcid":false,"given":"David","family":"Aebisher","sequence":"additional","affiliation":[{"name":"Department of Photomedicine and Physical Chemistry, Faculty of Medicine, Collegium Medicum, University of Rzeszow, 35-310 Rzeszow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Cataldi, C., Karao\u011flan, B.B., Liotta, E., and De Dosso, S. (2026). Decoding Immunotherapy Response in Colorectal Cancer: Translational Insights Beyond MSI. Cancers, 18.","DOI":"10.3390\/cancers18050852"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1093\/jnci\/djz093","article-title":"Immunotherapy for Colorectal Cancer: A Review of Current and Novel Therapeutic Approaches","volume":"111","author":"Franke","year":"2019","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Yu, B., Kang, J., Lei, H., Li, Z., Yang, H., and Zhang, M. (2024). Immunotherapy for colorectal cancer. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1433315"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"511","DOI":"10.18053\/jctres.07.202104.016","article-title":"Immunotherapy in microsatellite instability metastatic colorectal cancer: Current status and future perspectives","volume":"7","author":"Motta","year":"2021","journal-title":"J. Clin. Transl. Res."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Ros, J., Baraibar, I., Saoudi, N., Rodriguez, M., Salv\u00e0, F., Tabernero, J., and \u00c9lez, E. (2023). Immunotherapy for Colorectal Cancer with High Microsatellite Instability: The Ongoing Search for Biomarkers. Cancers, 15.","DOI":"10.3390\/cancers15174245"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer","volume":"383","author":"Shiu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2017.76.9901","article-title":"Durable Clinical Benefit with Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient\/Microsatellite Instability-High Metastatic Colorectal Cancer","volume":"36","author":"Overman","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1200\/JCO.21.01015","article-title":"First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High\/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study","volume":"40","author":"Lenz","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.2147\/OTT.S500281","article-title":"Progress of Immune Checkpoint Inhibitors Therapy for pMMR\/MSS Metastatic Colorectal Cancer","volume":"17","author":"Qu","year":"2024","journal-title":"Onco Targets Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"495","DOI":"10.37349\/etat.2024.00231","article-title":"Resistance to immune checkpoint inhibitors in colorectal cancer with deficient mismatch repair\/microsatellite instability: Misdiagnosis, pseudoprogression and\/or tumor heterogeneity?","volume":"5","author":"Normanno","year":"2024","journal-title":"Explor. Target. Antitumor Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e343","DOI":"10.1002\/mco2.343","article-title":"Hot and cold tumors: Immunological features and the therapeutic strategies","volume":"4","author":"Wang","year":"2023","journal-title":"MedComm"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Zheng, Z., Wieder, T., Mauerer, B., Sch\u00e4fer, L., Kesselring, R., and Braum\u00fcller, H. (2023). T Cells in Colorectal Cancer: Unravelling the Function of Different T Cell Subsets in the Tumor Microenvironment. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241411673"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Mezheyeuski, A., Micke, P., Mart\u00edn-Bernab\u00e9, A., Backman, M., Hrynchyk, I., Hammarstr\u00f6m, K., Str\u00f6m, S., Ekstr\u00f6m, J., Edqvist, P.H., and Sundstr\u00f6m, M. (2021). The Immune Landscape of Colorectal Cancer. Cancers, 13.","DOI":"10.3390\/cancers13215545"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/978-3-030-38862-1_6","article-title":"The Paradox of Cancer Immune Exclusion: Immune Oncology Next Frontier","volume":"180","author":"Pai","year":"2020","journal-title":"Cancer Treat. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"240","DOI":"10.4251\/wjgo.v15.i2.240","article-title":"\u201cCold\u201d colorectal cancer faces a bottleneck in immunotherapy","volume":"15","author":"Liu","year":"2023","journal-title":"World J. Gastrointest. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"55","DOI":"10.4251\/wjgo.v15.i1.55","article-title":"Challenges and exploration for immunotherapies targeting cold colorectal cancer","volume":"15","author":"Li","year":"2023","journal-title":"World J. Gastrointest. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Wu, Y., Zhuang, J., Qu, Z., Yang, X., and Han, S. (2023). Advances in immunotyping of colorectal cancer. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1259461"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1007\/s00262-023-03520-5","article-title":"PD-1 and PD-L1 inhibitors in cold colorectal cancer: Challenges and strategies","volume":"72","author":"Lin","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1007\/s11912-024-01583-w","article-title":"Immunotherapy for Microsatellite-Stable Metastatic Colorectal Cancer: Can we close the Gap between Potential and Practice?","volume":"26","author":"Hamid","year":"2024","journal-title":"Curr. Oncol. Rep."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Gilson, A., Tan, V., Koessler, T., Meyer, J., Meurette, G., Liot, \u00c9., Ris, F., and Delaune, V. (2025). Immune Checkpoint Inhibitors for Metastatic Colorectal Cancer: A Systematic Review. Cancers, 17.","DOI":"10.3390\/cancers17132125"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"198","DOI":"10.17305\/bjbms.2022.8286","article-title":"Intrinsic resistance and efficacy of immunotherapy in microsatellite instability-high colorectal cancer: A systematic review and meta-analysis","volume":"23","author":"Wang","year":"2023","journal-title":"Biomol. Biomed."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ejca.2022.03.017","article-title":"Pembrolizumab and maraviroc in refractory mismatch repair proficient\/microsatellite-stable metastatic colorectal cancer\u2014The PICCASSO phase I trial","volume":"167","author":"Haag","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"81","DOI":"10.5306\/wjco.v14.i2.81","article-title":"Therapeutic challenge for immunotherapy targeting cold colorectal cancer: A narrative review","volume":"14","author":"Ma","year":"2023","journal-title":"World J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e580","DOI":"10.1093\/oncolo\/oyae013","article-title":"The Efficacy of Immune Checkpoint Inhibitors in Microsatellite Stable Colorectal Cancer: A Systematic Review","volume":"29","author":"Guven","year":"2024","journal-title":"Oncologist"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e1188","DOI":"10.1634\/theoncologist.2020-0161","article-title":"Regorafenib and Nivolumab or Pembrolizumab Combination and Circulating Tumor DNA Response Assessment in Refractory Microsatellite Stable Colorectal Cancer","volume":"25","author":"Wang","year":"2020","journal-title":"Oncologist"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.annonc.2026.03.005","article-title":"Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"37","author":"Cremolini","year":"2026","journal-title":"Ann. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Baraibar, I., Mirallas, O., Saoudi, N., Ros, J., Salv\u00e0, F., Tabernero, J., and \u00c9lez, E. (2021). Combined Treatment with Immunotherapy-Based Strategies for MSS Metastatic Colorectal Cancer. Cancers, 13.","DOI":"10.3390\/cancers13246311"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1634\/theoncologist.2019-0244","article-title":"Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence","volume":"25","author":"Klempner","year":"2020","journal-title":"Oncologist"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Cornel, A.M., Mimpen, I.L., and Nierkens, S. (2020). MHC Class I Downregulation in Cancer: Underlying Mechanisms and Potential Targets for Cancer Immunotherapy. Cancers, 12.","DOI":"10.3390\/cancers12071760"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Dhatchinamoorthy, K., Colbert, J.D., and Rock, K.L. (2021). Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.636568"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s40425-015-0089-6","article-title":"A new paradigm for tumor immune escape: \u03b2-catenin-driven immune exclusion","volume":"3","author":"Spranger","year":"2015","journal-title":"J. Immunother. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1158\/1078-0432.CCR-18-1942","article-title":"WNT\/\u03b2-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers","volume":"25","author":"Luke","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13045-019-0804-8","article-title":"Tumor-intrinsic signaling pathways: Key roles in the regulation of the immunosuppressive tumor microenvironment","volume":"12","author":"Yang","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"D\u0105browska, A., Grubba, M., Balihodzic, A., Szot, O., Sobocki, B.K., and Perdyan, A. (2023). The Role of Regulatory T Cells in Cancer Treatment Resistance. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241814114"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"11795549211035540","DOI":"10.1177\/11795549211035540","article-title":"Targeting MDSC for Immune-Checkpoint Blockade in Cancer Immunotherapy: Current Progress and New Prospects","volume":"15","author":"Li","year":"2021","journal-title":"Clin. Med. Insights Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41698-024-00522-z","article-title":"Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance","volume":"8","author":"Wang","year":"2024","journal-title":"npj Precis. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Ceci, C., Atzori, M.G., Lacal, P.M., and Graziani, G. (2020). Targeting Tumor-Associated Macrophages to Increase the Efficacy of Immune Checkpoint Inhibitors: A Glimpse into Novel Therapeutic Approaches for Metastatic Melanoma. Cancers, 12.","DOI":"10.3390\/cancers12113401"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Zhou, X., Ni, Y., Liang, X., Lin, Y., An, B., He, X., and Zhao, X. (2022). Mechanisms of tumor resistance to immune checkpoint blockade and combination strategies to overcome resistance. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.915094"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1038\/s41416-020-1020-6","article-title":"T-cell tumour exclusion and immunotherapy resistance: A role for CAF targeting","volume":"123","author":"Hanley","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s00281-022-00977-x","article-title":"CAF-immune cell crosstalk and its impact in immunotherapy","volume":"45","author":"Maia","year":"2023","journal-title":"Semin. Immunopathol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1172\/JCI45817","article-title":"Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors","volume":"122","author":"Salmon","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/s41420-024-02146-5","article-title":"The role of cancer-associated fibroblasts and exosomal miRNAs-mediated intercellular communication in the tumor microenvironment and the biology of carcinogenesis: A systematic review","volume":"10","author":"Nedaeinia","year":"2024","journal-title":"Cell Death Discov."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1158\/2159-8290.CD-21-1714","article-title":"Spatial Positioning and Matrix Programs of Cancer-Associated Fibroblasts Promote T-cell Exclusion in Human Lung Tumors","volume":"12","author":"Grout","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: Opportunities and challenges","volume":"15","author":"Fukumura","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3892\/ol.2022.13489","article-title":"Immunosuppressive effects of vascular endothelial growth factor","volume":"24","author":"Ribatti","year":"2022","journal-title":"Oncol. Lett."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Hao, Z.N., Tan, X.P., Zhang, Q., Li, J., Xia, R., and Ma, Z. (2024). Lactate and Lactylation: Dual Regulators of T-Cell-Mediated Tumor Immunity and Immunotherapy. Biomolecules, 14.","DOI":"10.3390\/biom14121646"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Zhai, L., Bell, A., Ladomersky, E., Lauing, K.L., Bollu, L., Sosman, J.A., Zhang, B., Wu, J.D., Miller, S.D., and Meeks, J.J. (2020). Immunosuppressive IDO in Cancer: Mechanisms of Action, Animal Models, and Targeting Strategies. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.01185"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Vito, A., El-Sayes, N., and Mossman, K. (2020). Hypoxia-Driven Immune Escape in the Tumor Microenvironment. Cells, 9.","DOI":"10.3390\/cells9040992"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Fu, Z., Mowday, A.M., Smaill, J.B., Hermans, I.F., and Patterson, A.V. (2021). Tumour Hypoxia-Mediated Immunosuppression: Mechanisms and Therapeutic Approaches to Improve Cancer Immunotherapy. Cells, 10.","DOI":"10.3390\/cells10051006"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"400","DOI":"10.4049\/jimmunol.1701041","article-title":"Metabolic Barriers to T Cell Function in Tumors","volume":"200","author":"Sugiura","year":"2018","journal-title":"J. Immunol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.chom.2023.04.010","article-title":"Fusobacterium nucleatum-derived succinic acid induces tumor resistance to immunotherapy in colorectal cancer","volume":"31","author":"Jiang","year":"2023","journal-title":"Cell Host Microbe"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.ebiom.2019.08.076","article-title":"Impact of the microbiome on checkpoint inhibitor treatment in patients with non-small cell lung cancer and melanoma","volume":"48","author":"Shaikh","year":"2019","journal-title":"EBioMedicine"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"von Itzstein, M.S., Gonugunta, A.S., Sheffield, T., Homsi, J., Dowell, J.E., Koh, A.Y., Raj, P., Fattah, F., Wang, Y., and Basava, V.S. (2022). Association between Antibiotic Exposure and Systemic Immune Parameters in Cancer Patients Receiving Checkpoint Inhibitor Therapy. Cancers, 14.","DOI":"10.3390\/cancers14051327"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Crespin, A., Le Bescop, C., de Gunzburg, J., Vitry, F., Zalcman, G., Cervesi, J., and Bandinelli, P.A. (2023). A systematic review and meta-analysis evaluating the impact of antibiotic use on the clinical outcomes of cancer patients treated with immune checkpoint inhibitors. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1075593"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"100738","DOI":"10.1016\/j.tranon.2019.12.010","article-title":"Resistance to Checkpoint Inhibition in Cancer Immunotherapy","volume":"13","author":"Barrueto","year":"2020","journal-title":"Transl. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.cell.2016.08.069","article-title":"Loss of IFN-\u03b3 Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy","volume":"167","author":"Gao","year":"2016","journal-title":"Cell"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1158\/2159-8290.CD-16-1223","article-title":"Primary Resistance to PD-1 Blockade Mediated by JAK1\/2 Mutations","volume":"7","author":"Shin","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/PPO.0000000000000303","article-title":"Mechanisms of Resistance to PD-1 and PD-L1 Blockade","volume":"24","author":"Nowicki","year":"2018","journal-title":"Cancer J."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Zhou, B., Gao, Y., Zhang, P., and Chu, Q. (2021). Acquired Resistance to Immune Checkpoint Blockades: The Underlying Mechanisms and Potential Strategies. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.693609"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Zhu, S., Wang, Y., Tang, J., and Cao, M. (2022). Radiotherapy induced immunogenic cell death by remodeling tumor immune microenvironment. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1074477"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.semradonc.2014.07.005","article-title":"Radiotherapy and immunogenic cell death","volume":"25","author":"Golden","year":"2015","journal-title":"Semin. Radiat. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e2201401","DOI":"10.1002\/smtd.202201401","article-title":"Radiation-Induced Immunogenic Cell Death for Cancer Radioimmunotherapy","volume":"7","author":"Liu","year":"2023","journal-title":"Small Methods"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s40259-019-00367-0","article-title":"Oncolytic Viruses: Priming Time for Cancer Immunotherapy","volume":"33","author":"Russell","year":"2019","journal-title":"BioDrugs"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13045-020-00922-1","article-title":"Oncolytic viruses for cancer immunotherapy","volume":"13","author":"Hemminki","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2038403","DOI":"10.1080\/2162402X.2022.2038403","article-title":"What\u2019s next in cancer immunotherapy?\u2014The promise and challenges of neoantigen vaccination","volume":"11","author":"Redwood","year":"2022","journal-title":"Oncoimmunology"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2120676","DOI":"10.1080\/2162402X.2022.2120676","article-title":"Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness","volume":"11","author":"Barnestein","year":"2022","journal-title":"Oncoimmunology"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Zhao, Y., Du, J., and Shen, X. (2023). Targeting myeloid-derived suppressor cells in tumor immunotherapy: Current, future and beyond. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1157537"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"237ra67","DOI":"10.1126\/scitranslmed.3007974","article-title":"Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy","volume":"6","author":"Highfill","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.immuni.2018.03.037","article-title":"TGF-\u03b2 Inhibition and Immunotherapy: Checkmate","volume":"48","author":"Ganesh","year":"2018","journal-title":"Immunity"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1152\/physrev.00038.2010","article-title":"Normalization of the vasculature for treatment of cancer and other diseases","volume":"91","author":"Goel","year":"2011","journal-title":"Physiol. Rev."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Hack, S.P., Zhu, A.X., and Wang, Y. (2020). Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1\/PD-L1 Pathways: Challenges and Opportunities. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.598877"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1002\/JLB.5RU0222-082R","article-title":"Direct and indirect regulation of the tumor immune microenvironment by VEGF","volume":"111","author":"Zhang","year":"2022","journal-title":"J. Leukoc. Biol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"eaak9670","DOI":"10.1126\/scitranslmed.aak9670","article-title":"Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade","volume":"9","author":"Schmittnaegel","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1158\/2326-6066.CIR-20-0791","article-title":"Fueling the Revolution: Targeting Metabolism to Enhance Immunotherapy","volume":"9","author":"Leone","year":"2021","journal-title":"Cancer Immunol. Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"102461","DOI":"10.1016\/j.ctrv.2022.102461","article-title":"Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy","volume":"110","author":"Fujiwara","year":"2022","journal-title":"Cancer Treat. Rev."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.pharmthera.2018.12.004","article-title":"Targeting indoleamine-2,3-dioxygenase in cancer: Scientific rationale and clinical evidence","volume":"196","author":"Ricciuti","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00281-018-0702-0","article-title":"Inhibiting IDO pathways to treat cancer: Lessons from the ECHO-301 trial and beyond","volume":"41","author":"Muller","year":"2019","journal-title":"Semin. Immunopathol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e007349","DOI":"10.1136\/jitc-2023-007349","article-title":"MCT4 blockade increases the efficacy of immune checkpoint blockade","volume":"11","author":"Babl","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"216824","DOI":"10.1016\/j.canlet.2024.216824","article-title":"Targeting tumor-intrinsic SLC16A3 to enhance anti-PD-1 efficacy via tumor immune microenvironment reprogramming","volume":"589","author":"Yu","year":"2024","journal-title":"Cancer Lett."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1158\/2326-6066.CIR-20-0111","article-title":"Lactate-Modulated Immunosuppression of Myeloid-Derived Suppressor Cells Contributes to the Radioresistance of Pancreatic Cancer","volume":"8","author":"Yang","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1172\/JCI131859","article-title":"Targeting glutamine metabolism enhances tumor-specific immunity by modulating suppressive myeloid cells","volume":"130","author":"Oh","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1126\/science.abf3363","article-title":"Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients","volume":"371","author":"Davar","year":"2021","journal-title":"Science"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1126\/science.abb5920","article-title":"Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients","volume":"371","author":"Baruch","year":"2021","journal-title":"Science"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"102315","DOI":"10.1016\/j.eclinm.2023.102315","article-title":"Fecal microbiota transplantation plus tislelizumab and fruquintinib in refractory microsatellite stable metastatic colorectal cancer: An open-label, single-arm, phase II trial (RENMIN-215)","volume":"66","author":"Zhao","year":"2023","journal-title":"EClinicalMedicine"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"5351","DOI":"10.62347\/XKUJ3012","article-title":"Updated outcomes and exploratory analysis of RENMIN-215: Tislelizumab plus fruquintinib and fecal microbiota transplantation in refractory microsatellite stable metastatic colorectal cancer","volume":"14","author":"Zhao","year":"2024","journal-title":"Am. J. Cancer Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.chom.2024.06.010","article-title":"Fecal microbiota transplantation improves anti-PD-1 inhibitor efficacy in unresectable or metastatic solid cancers refractory to anti-PD-1 inhibitor","volume":"32","author":"Kim","year":"2024","journal-title":"Cell Host Microbe"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1126\/science.aaz7015","article-title":"Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response","volume":"374","author":"Spencer","year":"2021","journal-title":"Science"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"433","DOI":"10.5217\/ir.2023.00019","article-title":"Gut microbiome on immune checkpoint inhibitor therapy and consequent immune-related colitis: A review","volume":"21","author":"Hwang","year":"2023","journal-title":"Intest. Res."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Wang, B., Yu, W., Jiang, H., Meng, X., Tang, D., and Liu, D. (2024). Clinical applications of STING agonists in cancer immunotherapy: Current progress and future prospects. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1485546"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"103105","DOI":"10.1016\/j.copbio.2024.103105","article-title":"Delivery of STING agonists for cancer immunotherapy","volume":"87","author":"Wang","year":"2024","journal-title":"Curr. Opin. Biotechnol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s11912-023-01361-0","article-title":"The Development of STING Agonists and Emerging Results as a Cancer Immunotherapy","volume":"25","author":"Hines","year":"2023","journal-title":"Curr. Oncol. Rep."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Rokade, S., Damani, A.M., Oft, M., and Emmerich, J. (2024). IL-2 based cancer immunotherapies: An evolving paradigm. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1433989"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"11548","DOI":"10.3390\/cimb46100686","article-title":"Interleukin-12 Delivery Strategies and Advances in Tumor Immunotherapy","volume":"46","author":"Dong","year":"2024","journal-title":"Curr. Issues Mol. Biol."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Jia, Z., Ragoonanan, D., Mahadeo, K.M., Gill, J., Gorlick, R., Shpal, E., and Li, S. (2022). IL12 immune therapy clinical trial review: Novel strategies for avoiding CRS-associated cytokines. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.952231"},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Fabian, K.P., Kowalczyk, J.T., Reynolds, S.T., and Hodge, J.W. (2022). Dying of Stress: Chemotherapy, Radiotherapy, and Small-Molecule Inhibitors in Immunogenic Cell Death and Immunogenic Modulation. Cells, 11.","DOI":"10.3390\/cells11233826"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/cac2.12539","article-title":"Immunologic tumor microenvironment modulators for turning cold tumors hot","volume":"44","author":"Khosravi","year":"2024","journal-title":"Cancer Commun."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2217\/imt.15.126","article-title":"Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma","volume":"8","author":"Hato","year":"2016","journal-title":"Immunotherapy"},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Giannone, G., Ghisoni, E., Genta, S., Scotto, G., Tuninetti, V., Turinetto, M., and Valabrega, G. (2020). Immuno-Metabolism and Microenvironment in Cancer: Key Players for Immunotherapy. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21124414"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2452277","DOI":"10.1080\/19490976.2025.2452277","article-title":"From chaos to order: Optimizing fecal microbiota transplantation for enhanced immune checkpoint inhibitors efficacy","volume":"17","author":"Lin","year":"2025","journal-title":"Gut Microbes"},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Nerdinger, Y.G., Binder, A.K., Bremm, F., Feuchter, N., Schaft, N., and D\u00f6rrie, J. (2025). STINGing Cancer: Development, Clinical Application, and Targeted Delivery of STING Agonists. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26189008"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/onc.2009.356","article-title":"Immunogenic death of colon cancer cells treated with oxaliplatin","volume":"29","author":"Tesniere","year":"2010","journal-title":"Oncogene"},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Guan, Y., Kraus, S.G., Quaney, M.J., Daniels, M.A., Mitchem, J.B., and Teixeiro, E. (2020). FOLFOX Chemotherapy Ameliorates CD8 T Lymphocyte Exhaustion and Enhances Checkpoint Blockade Efficacy in Colorectal Cancer. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.00586"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"e1433981","DOI":"10.1080\/2162402X.2018.1433981","article-title":"PD-1\/PD-L1 pathway: An adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer","volume":"7","author":"Dosset","year":"2018","journal-title":"Oncoimmunology"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"e008409","DOI":"10.1136\/jitc-2023-008409","article-title":"Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: Phase 2 results from the CheckMate 9X8 randomized clinical trial","volume":"12","author":"Lenz","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/S1470-2045(22)00274-1","article-title":"Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): A multicentre, open-label, randomised, controlled, phase 2 trial","volume":"23","author":"Antoniotti","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/mc.23183","article-title":"Immunogenic cell death in colon cancer prevention and therapy","volume":"59","author":"Ruan","year":"2020","journal-title":"Mol. Carcinog."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"EAAG1266","DOI":"10.1126\/sciimmunol.aag1266","article-title":"The intersection of radiotherapy and immunotherapy: Mechanisms and clinical implications","volume":"1","author":"Spiotto","year":"2016","journal-title":"Sci. Immunol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13073-019-0653-7","article-title":"Radiation therapy and anti-tumor immunity: Exposing immunogenic mutations to the immune system","volume":"11","author":"Lhuillier","year":"2019","journal-title":"Genome Med."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Buchwald, Z.S., Wynne, J., Nasti, T.H., Zhu, S., Mourad, W.F., Yan, W., Gupta, S., Khleif, S.N., and Khan, M.K. (2018). Radiation, Immune Checkpoint Blockade and the Abscopal Effect: A Critical Review on Timing, Dose and Fractionation. Front. Oncol., 8.","DOI":"10.3389\/fonc.2018.00612"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1158\/1078-0432.CCR-20-4632","article-title":"A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer","volume":"27","author":"Monjazeb","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1038\/s43018-021-00269-7","article-title":"Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial","volume":"2","author":"Parikh","year":"2021","journal-title":"Nat. Cancer"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"813","DOI":"10.2147\/ITT.S494670","article-title":"Immune Checkpoint Inhibitor Combined with Antiangiogenic Agent Synergistically Improving the Treatment Efficacy for Solid Tumors","volume":"13","author":"Zhou","year":"2024","journal-title":"Immunotargets Ther."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"15330338251334209","DOI":"10.1177\/15330338251334209","article-title":"Combining Cetuximab and Immunotherapy for Treating MSS\/pMMR Colorectal Cancer: Current Evidence and Challenges","volume":"24","author":"Pei","year":"2025","journal-title":"Technol. Cancer Res. Treat."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1001\/jamaoncol.2021.2915","article-title":"Cetuximab Rechallenge Plus Avelumab in Pretreated Patients with RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial","volume":"7","author":"Martinelli","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Yarchoan, M., Mohan, A.A., Dennison, L., Vithayathil, T., Ruggieri, A., Lesinski, G.B., Armstrong, T.D., Azad, N.S., and Jaffee, E.M. (2019). MEK inhibition suppresses B regulatory cells and augments anti-tumor immunity. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0224600"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S1470-2045(19)30027-0","article-title":"Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): A multicentre, open-label, phase 3, randomised, controlled trial","volume":"20","author":"Eng","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Kim, C.W., Chon, H.J., and Kim, C. (2021). Combination Immunotherapies to Overcome Intrinsic Resistance to Checkpoint Blockade in Microsatellite Stable Colorectal Cancer. Cancers, 13.","DOI":"10.3390\/cancers13194906"},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Ros, J., Balconi, F., Baraibar, I., Saoudi Gonzalez, N., Salva, F., Tabernero, J., and Elez, E. (2023). Advances in immune checkpoint inhibitor combination strategies for microsatellite stable colorectal cancer. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1112276"},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Makaremi, S., Asadzadeh, Z., Hemmat, N., Baghbanzadeh, A., Sgambato, A., Ghorbaninezhad, F., Safarpour, H., Argentiero, A., Brunetti, O., and Bernardini, R. (2021). Immune Checkpoint Inhibitors in Colorectal Cancer: Challenges and Future Prospects. Biomedicines, 9.","DOI":"10.3390\/biomedicines9091075"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"e2149040","DOI":"10.1001\/jamanetworkopen.2021.49040","article-title":"Assessment of Capecitabine and Bevacizumab with or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial","volume":"5","author":"Mettu","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"100559","DOI":"10.1016\/j.esmoop.2022.100559","article-title":"MODUL cohort 2: An adaptable, randomized, signal-seeking trial of fluoropyrimidine plus bevacizumab with or without atezolizumab maintenance therapy for BRAFwtmetastatic colorectal cancer","volume":"7","author":"Tabernero","year":"2022","journal-title":"ESMO Open"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.dld.2022.04.024","article-title":"FFCD 1709-SIRTCI phase II trial: Selective internal radiation therapy plus Xelox, Bevacizumab and Atezolizumab in liver-dominant metastatic colorectal cancer","volume":"54","author":"Randrian","year":"2022","journal-title":"Dig. Liver Dis."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1038\/s41591-024-03083-7","article-title":"Botensilimab plus balstilimab in relapsed\/refractory microsatellite stable metastatic colorectal cancer: A phase 1 trial","volume":"30","author":"Bullock","year":"2024","journal-title":"Nat. Med."},{"key":"ref_128","first-page":"118","article-title":"Pembrolizumab Plus mFOLFOX7 or FOLFIRI for Microsatellite Stable\/Mismatch Repair-Proficient Metastatic Colorectal Cancer: KEYNOTE-651 Cohorts B and D","volume":"23","author":"Kim","year":"2024","journal-title":"Clin. Colorectal Cancer"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.2147\/IJGM.S408349","article-title":"Immune Checkpoint Inhibitor-Based Combination Therapy for Colorectal Cancer: An Overview","volume":"16","author":"Li","year":"2023","journal-title":"Int. J. Gen. Med."},{"key":"ref_130","first-page":"285","article-title":"Safety and Efficacy of Vicriviroc (MK-7690) in Combination with Pembrolizumab in Patients with Advanced or Metastatic Microsatellite Stable Colorectal Cancer","volume":"23","author":"Bessudo","year":"2024","journal-title":"Clin. Colorectal Cancer"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"7255","DOI":"10.1038\/s41467-024-51536-x","article-title":"Tislelizumab plus cetuximab and irinotecan in refractory microsatellite stable and RAS wild-type metastatic colorectal cancer: A single-arm phase 2 study","volume":"15","author":"Xu","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/j.ccell.2025.08.002","article-title":"Phase 1\/2 trial of encorafenib, cetuximab, and nivolumab in microsatellite stable BRAFV600Emetastatic colorectal cancer","volume":"43","author":"Morris","year":"2025","journal-title":"Cancer Cell"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1158\/1078-0432.CCR-24-0268","article-title":"Plasma versus Tissue Tumor Mutational Burden as Biomarkers of Durvalumab plus Tremelimumab Response in Patients with Metastatic Colorectal Cancer in the CO.26 Trial","volume":"30","author":"Loree","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Hou, W., Yi, C., and Zhu, H. (2022). Predictive biomarkers of colon cancer immunotherapy: Present and future. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1032314"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000496565","article-title":"Immunologic Biomarkers and Biomarkers for Immunotherapies in Gastrointestinal Cancer","volume":"35","author":"Martin","year":"2019","journal-title":"Visc. Med."},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Mlecnik, B., Lugli, A., Bindea, G., Marliot, F., Bifulco, C., Lee, J.J., Zlobec, I., Rau, T.T., Berger, M.D., and Nagtegaal, I.D. (2023). Multicenter International Study of the Consensus Immunoscore for the Prediction of Relapse and Survival in Early-Stage Colon Cancer. Cancers, 15.","DOI":"10.3390\/cancers15020418"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13148-021-01226-y","article-title":"Pembrolizumab plus azacitidine in patients with chemotherapy refractory metastatic colorectal cancer: A single-arm phase 2 trial and correlative biomarker analysis","volume":"14","author":"Kuang","year":"2022","journal-title":"Clin. Epigenet."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41568-020-0285-7","article-title":"The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy","volume":"20","author":"Bruni","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/modpathol.2017.156","article-title":"Implications of the tumor immune microenvironment for staging and therapeutics","volume":"31","author":"Taube","year":"2018","journal-title":"Mod. Pathol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1158\/1078-0432.CCR-18-1851","article-title":"The Immunoscore: Colon Cancer and Beyond","volume":"26","author":"Angell","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s10238-024-01408-x","article-title":"Biomarkers to predict efficacy of immune checkpoint inhibitors in colorectal cancer patients: A systematic review and meta-analysis","volume":"24","author":"Yu","year":"2024","journal-title":"Clin. Exp. Med."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1038\/s41591-022-02084-8","article-title":"Whole-body CD8+ T cell visualization before and during cancer immunotherapy: A phase 1\/2 trial","volume":"28","author":"Giesen","year":"2022","journal-title":"Nat. Med."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.7150\/thno.79976","article-title":"In vivo imaging of CD8+ T cells in metastatic cancer patients: First clinical experience with simultaneous [89Zr]Zr-Df-IAB22M2C PET\/MRI","volume":"13","author":"Schwenck","year":"2023","journal-title":"Theranostics"},{"key":"ref_144","first-page":"720","article-title":"CD8-Targeted PET Imaging of Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study of 89Zr-Df-IAB22M2C, a Radiolabeled Anti-CD8 Minibody","volume":"63","author":"Farwell","year":"2022","journal-title":"J. Nucl. Med."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1148\/radiol.210518","article-title":"Emerging and Evolving Concepts in Cancer Immunotherapy Imaging","volume":"306","author":"Dercle","year":"2023","journal-title":"Radiology"},{"key":"ref_146","first-page":"97","article-title":"Radiomic biomarkers of tumor immune biology and immunotherapy response","volume":"28","author":"Wang","year":"2021","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Han, X., Cao, W., Wu, L., and Liang, C. (2022). Radiomics Assessment of the Tumor Immune Microenvironment to Predict Outcomes in Breast Cancer. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.773581"},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Saad, E.D., Coart, E., Deltuvaite-Thomas, V., Garcia-Barrado, L., Burzykowski, T., and Buyse, M. (2023). Trial Design for Cancer Immunotherapy: A Methodological Toolkit. Cancers, 15.","DOI":"10.3390\/cancers15184669"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"djx013","DOI":"10.1093\/jnci\/djx013","article-title":"Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements","volume":"109","author":"Korn","year":"2017","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/1750743X.2026.2639275","article-title":"Financial barriers to immunotherapy: Challenges and potential mitigation strategies: A review paper","volume":"18","author":"Numan","year":"2026","journal-title":"Immunotherapy"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1111\/jgh.70420","article-title":"Circulating Tumor DNA and Precision Biomarkers in Colorectal Cancer: Implications for Diagnosis, Monitoring, and Management of Advanced Disease","volume":"41","author":"Srinivasalu","year":"2026","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"Hijazi, A., Bifulco, C., Baldin, P., and Galon, J. (2024). Digital Pathology for Better Clinical Practice. Cancers, 16.","DOI":"10.3390\/cancers16091686"},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"Zhou, Z., and Zhou, J. (2026). Beyond prediction: AI as a mechanistic microscope and digital twin for colorectal cancer immunotherapy. Front. Immunol., 17.","DOI":"10.3389\/fimmu.2026.1746927"},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Wang, Y., Huang, P., Li, C., Tu, S., and Yang, H. (2025). PLGA-based nanoparticles in colorectal cancer immunotherapy: Current concepts and future perspectives. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1714460"},{"key":"ref_155","doi-asserted-by":"crossref","unstructured":"Wu, J., Wang, X., Wang, Y., Xun, Z., and Li, S. (2024). Application of PLGA in Tumor Immunotherapy. Polymers, 16.","DOI":"10.3390\/polym16091253"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"114915","DOI":"10.1016\/j.jconrel.2026.114915","article-title":"Nanomedicine for colorectal cancer therapy by remodeling the immune microenvironment","volume":"394","author":"Wu","year":"2026","journal-title":"J. Control. Release"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"106723","DOI":"10.4251\/wjgo.v17.i7.106723","article-title":"Adoptive cell therapy in colorectal cancer: Advances in chimeric antigen receptor T cells","volume":"17","author":"Chen","year":"2025","journal-title":"World J. Gastrointest. Oncol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"314","DOI":"10.3343\/alm.2023.0382","article-title":"Manufacturing Cell and Gene Therapies: Challenges in Clinical Translation","volume":"44","author":"Lee","year":"2024","journal-title":"Ann. Lab. Med."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/31\/17\/3124\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T09:27:00Z","timestamp":1788773220000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/31\/17\/3124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,6]]},"references-count":158,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["molecules31173124"],"URL":"https:\/\/doi.org\/10.3390\/molecules31173124","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,6]]}}}